{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:26:15Z","timestamp":1770499575271,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSci"],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1208\/ps020107","type":"journal-article","created":{"date-parts":[[2003,8,8]],"date-time":"2003-08-08T10:41:42Z","timestamp":1060339302000},"page":"59-67","source":"Crossref","is-referenced-by-count":14,"title":["Synthesis and characterization of positively charged tPA as a prodrug using a heparin\/protamine-based drug-delivery system"],"prefix":"10.1208","volume":"2","author":[{"given":"Jun F.","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen E.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2000,3,21]]},"reference":[{"key":"210059_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1054-3589(08)60222-7","volume":"12","author":"DA Cooney","year":"1975","unstructured":"Cooney DA, Rosenbluth RJ. Enzymes as therapeutic agents. Adv Pharmacol Chemother, 1975; 12: 185\u2013289.","journal-title":"Adv Pharmacol Chemother"},{"key":"210059_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0014-827X(99)00066-X","volume":"54","author":"FM Veronese","year":"1999","unstructured":"Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco, 1999; 54: 497\u2013516.","journal-title":"Farmaco"},{"key":"210059_CR3","first-page":"346","volume":"28","author":"S Mumtaz","year":"1991","unstructured":"Mumtaz S, Bachhawat BK. Conjugation of proteins and enzymes with hydrophilic polymers and their applications. Indian J Biochem Biophys, 1991; 28: 346\u201351.","journal-title":"Indian J Biochem Biophys"},{"key":"210059_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.1999.tb08495.x","volume":"875","author":"TM Chang","year":"1999","unstructured":"Chang TM. Artificial cells, encapsulation, and immobilization. Ann NY Acad Sci, 1999; 875: 71\u201383.","journal-title":"Ann NY Acad Sci"},{"key":"210059_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V68.1.275.275","volume":"68","author":"RB Stricker","year":"1986","unstructured":"Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood, 1986; 68; 275\u2013280.","journal-title":"Blood"},{"key":"210059_CR6","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0021-9258(18)94374-7","volume":"244","author":"VJ Marder","year":"1969","unstructured":"Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin II. Mechanism of their anticoagulant activity. J Biol Chem, 1969; 244: 2120\u20132124.","journal-title":"J Biol Chem"},{"key":"210059_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.me.39.020188.002201","volume":"39","author":"D Collen","year":"1988","unstructured":"Collen D, Stump DC, Gold HK. Thrombolytic therapy Annu Rev Med, 1988: 39: 405\u2013423.","journal-title":"Annu Rev Med"},{"key":"210059_CR8","doi-asserted-by":"crossref","first-page":"46G","DOI":"10.1016\/0002-9149(93)90107-N","volume":"72","author":"D Collen","year":"1993","unstructured":"Collen D, Lijnen HR. On the future of thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 1993; 72: 46G-50G.","journal-title":"Am J Cardiol"},{"key":"210059_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0140-6736(93)91888-S","volume":"342","author":"D Collen","year":"1993","unstructured":"Collen D. Towards improved thrombolytic therapy. Lancet. 1993; 342: 34\u201336.","journal-title":"Lancet"},{"key":"210059_CR10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1055\/s-0038-1646377","volume":"66","author":"HR Lijmen","year":"1991","unstructured":"Lijmen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost, 1991; 66: 88\u2013110.","journal-title":"Thromb Haemost"},{"key":"210059_CR11","first-page":"1341","volume-title":"Gilman\u2019s The Pharmacological Basis of Therapentics","author":"PW Majerus","year":"1995","unstructured":"Majerus PW, Bronze Jr GJ, Miletich JP, Tollefsen DM Anticoagulant, thrombolytics, and antiplatelet drugs In: Gilman\u2019s The Pharmacological Basis of Therapentics 9th ed. New York: McGraw-Hill, 1995; 1341\u20131359.","edition":"9th ed."},{"key":"210059_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJM199307293290527","volume":"329","author":"HV Anderson","year":"1993","unstructured":"Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction [see comments]. N Engl J Med. 1993; 329: 703\u2013709.","journal-title":"N Engl J Med"},{"key":"210059_CR13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s002770050195","volume":"73","author":"K Huber","year":"1996","unstructured":"Huber K, Runge MS, Bode C, Gulba D. Thrombolytic therapy in acute myocardial infarction update 1996. Ann Hematol. 1996; 73: S29\u201338.","journal-title":"Ann Hematol"},{"key":"210059_CR14","doi-asserted-by":"crossref","first-page":"M638","DOI":"10.1097\/00002480-199809000-00068","volume":"44","author":"Y Byun","year":"1998","unstructured":"Byun Y, Yang VC. Delivery system for targeted thrombolysis without the risk of hemorrhage. ASAIO J. 1998; 44: M638-M641.","journal-title":"ASAIO J."},{"key":"210059_CR15","first-page":"131","volume-title":"Tissue Plasminogen Activator in Thrombolytic Therapy","author":"AGG Turpie","year":"1987","unstructured":"Turpie AGG. Thrombolytic therapy in venous thromboembolism. In: Sobel BE, Collen D, Grossbard EB. eds. Tissue Plasminogen Activator in Thrombolytic Therapy. New York: Marcel Dekker. 1987; 131\u2013146."},{"key":"210059_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02798362","volume":"16","author":"H Bernstein","year":"1987","unstructured":"Bernstein H, Yang VC, Langer R. An investigation of heparinase immobilization. Appl Biochem Biotechnol. 1987; 16: 129\u2013143.","journal-title":"Appl Biochem Biotechnol"},{"key":"210059_CR17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2460\/ajvr.1996.57.08.1124","volume":"57","author":"A Lanevschi","year":"1996","unstructured":"Lanevschi A, Kramer JW, Greene SA, Meyers KM. Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs. Am J Vet Res. 1996; 57: 1124\u20131130.","journal-title":"Am J Vet Res"},{"key":"210059_CR18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/elan.1140050903","volume":"5","author":"JH Yun","year":"1993","unstructured":"Yun JH, Ma SC, Fu B, Yang VC, Meyerhoff ME. Direct potentiometric membrane-electrode measurements of heparin-binding to macromolecule. Electroanalysis. 1993; 5: 719\u2013724.","journal-title":"Electroanalysis"},{"key":"210059_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0049-3848(98)00201-1","volume":"94","author":"Y Byun","year":"1999","unstructured":"Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential non-toxic heparin antagonist. Thromb Res. 1999; 94: 53\u201361.","journal-title":"Thromb Res"},{"key":"210059_CR20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/abio.1998.2947","volume":"266","author":"N Ramamurthy","year":"1999","unstructured":"Ramamurthy N, Baliga N, Wakefield TW, Andrews PC. Yang VC, Meyerhoff ME. Determination of low molecular weight heparins and their binding to protamine and a protamine analogue using polyion-sensitive membrane electrodes. Anal Biochem, 1999; 266: 116\u2013124.","journal-title":"Anal Biochem"},{"key":"210059_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/01.CIR.68.2.462","volume":"68","author":"D Collen","year":"1983","unstructured":"Collen D, Verstraete M. Systemic thrombolytic therapy of acute myocardial infarction? Circul. 1983; 68: 462\u2013465.","journal-title":"Circul"},{"key":"210059_CR22","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0006-2952(84)90536-7","volume":"33","author":"KA Fox","year":"1984","unstructured":"Fox KA, Bergmann SR, Sobel BE. Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA). Biochem Pharmacol. 1984; 33. 1831\u20131838.","journal-title":"Biochem Pharmacol"},{"key":"210059_CR23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1172\/JCI113001","volume":"79","author":"J Owen","year":"1987","unstructured":"Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase or tissue plasminogen activator. J Clin Invest. 1987; 79: 1642\u20131647.","journal-title":"J Clin Invest"},{"key":"210059_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"AK Rao","year":"1988","unstructured":"Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial phase 1: hemorrhagic manifestation and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11: 1\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"210059_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.77.2.353","volume":"77","author":"M Verstraete","year":"1988","unstructured":"Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation, 1988; 77: 353\u2013360.","journal-title":"Circulation"},{"key":"210059_CR26","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","volume":"98","author":"MN Levine","year":"1990","unstructured":"Levine MN, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AGG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990; 98: 1473\u20131479.","journal-title":"Chest"}],"container-title":["AAPS PharmSci"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/ps020107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/ps020107\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/ps020107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:59:14Z","timestamp":1734094754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/ps020107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["210059"],"URL":"https:\/\/doi.org\/10.1208\/ps020107","relation":{},"ISSN":["1522-1059"],"issn-type":[{"value":"1522-1059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}